On September 26, Hangzhou Matridx Biotechnology Co., Ltd. (hereinafter referred to as Matridx) announced that it had completed a strategic investment of hundreds of millions of yuan. This round of financing is jointly led by Alibaba and Huatai Zijin, and the old shareholders such as Qianhai FOF and Proxima Ventures continue to increase their stakes. Haoyue Capital serves as the exclusive financial adviser for this round of financing. This round of financing is mainly used for new product R & D, registration and certification, and further promoting the national commercialization application strategy.

Hangzhou Matridx Biotechnology Co., Ltd. is an innovative technology enterprise which focuses on the molecular diagnosis of infectious diseases, the headquarter is located in Hangzhou, Zhejiang. The company committed to use the leading diagnostic technology to promote the changes of diagnosis of infectious diseases, to make the diagnosis more simple, more rapid and more intelligent. It utilizes gene editing (CRISPR/Cas) and high-throughput sequencing (NGS) as the technology platforms, Layout a number of core technology and patents , has already built Multi-level, high-quality product lines and service system in the area of diagnosis of infectious diseases, and can provide the total solution for patients.

Through years of R&D and clinical application practices, Hangzhou Matridx has developed an automated Library prep instrument, becomes the only one company who can provide the microbial mNGS full automation solution in China. They have obtained nearly 20 patents, and have very close business relationships with Top Clinical institutions such as Peking Union Medical College Hospital, Huashan Hospital of the Shanghai FuDan University, Guangzhou Institute of Respiratory Health,  to build the AI diagnosis system based on Big Database. The company will adhere to the concept of "Innovative Diagnostics For The Future" and aspire to become a leader in the field of infectious disease diagnosis.

In terms of market coverage, Matridx has the largest and widest network of mNGS testing and delivery centers in China. At present, through self and joint construction with medical institutions, Matridx has established regional mNGS testing and delivery centers in 17 provinces and cities across the country, and the service network has achieved full coverage in all provinces in mainland China. The company has established in-depth cooperative relations with domestic top clinical institutions such as Peking Union Medical College Hospital of Chinese Academy of Medical Sciences, Huashan Hospital Affiliated to Fudan University and Guangzhou Institute of respiratory health, which has carried out the construction of macrogenomics platform with many regional benchmark hospitals to jointly promote the clinical application of infectious mNGS.